266 related articles for article (PubMed ID: 9475279)
1. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development.
Sanchez LS; de la Monte SM; Filippov G; Jones RC; Zapol WM; Bloch KD
Pediatr Res; 1998 Feb; 43(2):163-8. PubMed ID: 9475279
[TBL] [Abstract][Full Text] [Related]
2. Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells.
Zhu B; Strada S; Stevens T
Am J Physiol Lung Cell Mol Physiol; 2005 Aug; 289(2):L196-206. PubMed ID: 15792963
[TBL] [Abstract][Full Text] [Related]
3. Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes.
Geng Y; Zhou L; Thompson WJ; Lotz M
J Biol Chem; 1998 Oct; 273(42):27484-91. PubMed ID: 9765278
[TBL] [Abstract][Full Text] [Related]
4. Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway.
Moreno L; Losada B; Cogolludo Al; Lodi F; Lugnier C; Villamor E; Moro M; Tamargo J; Pérez-Vizcaíno F
Pediatr Res; 2004 Oct; 56(4):563-70. PubMed ID: 15295092
[TBL] [Abstract][Full Text] [Related]
5. Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7- (2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5).
Kotera J; Fujishige K; Michibata H; Yuasa K; Kubo A; Nakamura Y; Omori K
Biochem Pharmacol; 2000 Nov; 60(9):1333-41. PubMed ID: 11008127
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
7. Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation.
Ni XP; Safai M; Gardner DG; Humphreys MH
Kidney Int; 2001 Apr; 59(4):1264-73. PubMed ID: 11260387
[TBL] [Abstract][Full Text] [Related]
8. Expression and activity of cGMP-dependent phosphodiesterases is up-regulated by lipopolysaccharide (LPS) in rat peritoneal macrophages.
Witwicka H; Kobiałka M; Siednienko J; Mitkiewicz M; Gorczyca WA
Biochim Biophys Acta; 2007 Feb; 1773(2):209-18. PubMed ID: 17141339
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats.
Cohen AH; Hanson K; Morris K; Fouty B; McMurty IF; Clarke W; Rodman DM
J Clin Invest; 1996 Jan; 97(1):172-9. PubMed ID: 8550830
[TBL] [Abstract][Full Text] [Related]
10. Selective blockade of phosphodiesterase types 2, 5 and 9 results in cyclic 3'5' guanosine monophosphate accumulation in retinal pigment epithelium cells.
Diederen RM; La Heij EC; Markerink-van Ittersum M; Kijlstra A; Hendrikse F; de Vente J
Br J Ophthalmol; 2007 Mar; 91(3):379-84. PubMed ID: 16943225
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling.
Kim D; Aizawa T; Wei H; Pi X; Rybalkin SD; Berk BC; Yan C
J Mol Cell Cardiol; 2005 Jan; 38(1):175-84. PubMed ID: 15623434
[TBL] [Abstract][Full Text] [Related]
12. Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation.
Jernigan NL; Resta TC
Am J Physiol Lung Cell Mol Physiol; 2002 Jun; 282(6):L1366-75. PubMed ID: 12003794
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance.
Kim D; Rybalkin SD; Pi X; Wang Y; Zhang C; Munzel T; Beavo JA; Berk BC; Yan C
Circulation; 2001 Nov; 104(19):2338-43. PubMed ID: 11696475
[TBL] [Abstract][Full Text] [Related]
14. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation.
Shimizu-Albergine M; Rybalkin SD; Rybalkina IG; Feil R; Wolfsgruber W; Hofmann F; Beavo JA
J Neurosci; 2003 Jul; 23(16):6452-9. PubMed ID: 12878685
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Turko IV; Ballard SA; Francis SH; Corbin JD
Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
[TBL] [Abstract][Full Text] [Related]
16. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity.
Hanson KA; Ziegler JW; Rybalkin SD; Miller JW; Abman SH; Clarke WR
Am J Physiol; 1998 Nov; 275(5):L931-41. PubMed ID: 9815111
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig.
Kruuse C; Khurana TS; Rybalkin SD; Birk S; Engel U; Edvinsson L; Olesen J
Eur J Pharmacol; 2005 Oct; 521(1-3):105-14. PubMed ID: 16182282
[TBL] [Abstract][Full Text] [Related]
18. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message.
Hanson KA; Burns F; Rybalkin SD; Miller JW; Beavo J; Clarke WR
Am J Respir Crit Care Med; 1998 Jul; 158(1):279-88. PubMed ID: 9655741
[TBL] [Abstract][Full Text] [Related]
19. Contribution of phosphodiesterase isoenzymes and cyclic nucleotide efflux to the regulation of cyclic GMP levels in aortic smooth muscle cells.
Mercapide J; Santiago E; Alberdi E; Martinez-Irujo JJ
Biochem Pharmacol; 1999 Nov; 58(10):1675-83. PubMed ID: 10535760
[TBL] [Abstract][Full Text] [Related]
20. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
